



## SpeedX expands STI Research offering with Key Multiplex Assay

*Maximize STI detection. Combine with AMR.*

**SYDNEY, AUSTRALIA – (July 11).** Innovative molecular diagnostic developer, SpeedX Pty. Ltd., have released a new Research Use Only (RUO) product providing an exciting expansion of their STI research offering. CT/GC/TV/MG**Plex**\* simultaneously detects *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (GC), *Trichomonas vaginalis* (TV), and *Mycoplasma genitalium* (MG) in a single-well multiplex qPCR/NAAT assay.

CT/GC/TV/MG**Plex** is the missing piece, paving the way for a streamlined STI research workflow providing maximal results, utilising open extraction and qPCR/NAAT platforms. From a single sample extraction, you can combine detection of these four key STI organisms, with the ability to determine antibiotic resistance with SpeedX's flagship Antimicrobial Resistance (AMR) products, **PlexPrime**<sup>®</sup> MG+23S and **PlexPrime**<sup>®</sup> GC+gryA.

*"By combining the open-system workflow cost and throughput benefits, with the ability to provide AMR mutation results, we've created a complete research solution for STI detection, suitable for both medium- and high-throughput laboratories",* remarked Colin Denver, CEO at SpeedX.

Ongoing research in this area is an important step in combatting this health burden. In 2018, the Centers for Disease Control and prevention (CDC) report 1 in 5 people in the US have an STI, with a total of nearly 68 million cases.<sup>1</sup> 2021 surveillance data highlights the ongoing threat of STIs to the US, noting over 700,000 cases of gonorrhea, which is a 28% increase in the past 4 years.<sup>2</sup> Antibiotic resistance in these organisms is having a huge impact on health economy. AMR is considered a global threat, and guidelines across US, EU, UK and AU support the use of AMR assays to detect antibiotic resistant STIs.

*"Researchers have been requesting an 'open' platform product like this, so we're very excited to meet this need",* says Jennifer Siegel, SpeedX VP of Sales, North America. *"With the added benefit of linking to antibiotic resistance assays, laboratories will glean so much information from a single sample."*

### About SpeedX Pty Ltd

Founded in 2009, SpeedX is a global company with offices in Austin, London and Sydney, and distributors across Europe. SpeedX specializes in molecular diagnostic solutions that go beyond simple detection to also offer comprehensive information on antibiotic resistance. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeedX please see: <https://plexpcr.com>

\*Research Use Only, not for use in diagnostic procedures

1 <https://www.cdc.gov/std/statistics/prevalence-incidence-cost-2020.htm>

2 <https://www.cdc.gov/std/statistics/infographic.htm>

### Contact:

Michelle Howie

Associate Director | Global Strategic Marketing

[michelleh@speedx.com.au](mailto:michelleh@speedx.com.au)

+61 499 743 199